NovaBiotics Chief Scientific Officer and Founder of the leading clinical-stage biotechnology company, Dr Deborah O'Neil, will be presenting at the biotechnology industry's largest event, the BIO International Convention in Washington, 27-30 June, giving an update on the technology and recent developments as well as outlining the Company's future plans.
Dr O'Neil will be presenting on Thursday, June 30 at 9.30am in the Capitol Hill suite.
The company is preparing to carry out a multi-centre phase IIb clinical study ("the study") for its' lead asset Novexatin® in 2011/2012 in the USA. Partnering discussions are ongoing in parallel with potential licensing partners.
Novexatin®, the company’s lead product, is a topical treatment for fungal nail infection and addresses a poorly served $3 billion global market. Novexatin® is a unique product, with clinical data derived thus far confirming that it addresses the profound safety and efficacy shortcomings of existing remedies for fungal nail infection. NovaBiotics’ data suggest a step change in patient care is possible with superior cure rates predicted by the IIb study following a month’s treatment rather than the 12 months required for current topical therapies.
Dr Deborah O’Neil and Professor Andy Porter will attend the event as part of the Scottish delegation. Dr Deborah O’Neil commented, “I am delighted that NovaBiotics has been selected to present at this year’s BIO International in Washington and that we’ll be able showcase our technology to a worldwide audience. This comes on top of an already packed partnering schedule through which we're looking forward to sharing recent exciting advances with Novexatin®, Lynovex™, Novamycin® and Novarifyn™ with existing and also new potential partners.
"Our discussions with the US Food and Drug Administration (FDA) are on track towards gaining investigational new drug (IND) approval for Novexatin® to facilitate a large, multi-centre phase IIb efficacy study, which will be a major milestone in this potentially world-beating technology's commercialisation journey."
Professor Andy Porter adds, "I am thrilled with the continued success of Novexatin but also have high hopes for our pipeline products which include Lynovex™ our dual muco-active anti-bacterial already showing exciting activity when compared with similar molecules, and Luminaderm® our OTC platform from which compounds are currently being assessed by some of the world’s largest consumer health players."
NovaBiotics Announces New Data on Cysteamine (Nylexa™) as an Antimicrobial Resistance Breaker in Multi Drug Resistant Bacteria | 18 June 2016
NovaBiotics Highlights Importance of Co-ordinated Approach to Antimicrobial Resistance | 7th June 2016
NovaBiotics Wins Investment of the Year Award | 5 Feb 2016
Lynovex® Activity in CF sputum & Against the Emerging CF Pathogen, Mycobacterium abscessus | 12 Aug 2015
Phase IIa clinical study results for NovaBiotics' Lynovex® presented at the 38th Annual European Cystic Fibrosis Symposium | 12 Jun 2015
Launch of the BEAM Alliance | 9 Jun 2015
NovaBiotics Quoted in "What Investment" on 11 February | 11 Feb 2015
NovaBiotics Raises £5.0 million in a Private Placement from Woodford Investment Management | 19 Jan 2015
NovaBiotics' Dr Deborah O'Neil Named EY UK Health Products & Services Entrepreneur of 2014 | 7 Oct 2014
Showcases increasing investor interest in the global stem cell sector | 22 Sep 2014
NovaBiotics Receives Orphan Drug Status from the US Food and Drug Administration (FDA) for Lynovex® | 16 Sep 2014
Scotland's Pharmacells Group creates 12 new jobs at BioCity Scotland following acquisition by Precious Cells Group, London | 18 August 2014
Precious Cells Biobank Acquires Stem Cell Technology Leader Pharmacells Group | 25 July 2014
NovaBiotics' Dr Deborah O'Neil Wins Entrepreneur of the Year | 27 June 2014
NovaBiotics Initiates Phase IIa Clinical Study for Lynovex in Cystic Fibrosis | 25 June 2014
NovaBiotics' Dr Deborah O'Neil Named EY Scotland Entrepreneur of 2014 | 20 June 2014
NovaBiotics Initiates Development of Orphan Drug in Cystic Fibrosis | 17 December 2013
Pharmacells to expand following funding boost | 24 September 2013
NovaBiotics Enters into Agreement with Taro | 28 August 2013
First patient dosed at Aberdeen Royal Infirmary in major international study | 29 August 2012
Pharmacells in talks to extend reach overseas | 24 January 2012
New hope in cystic fibrosis fight as Scots patients first to test drug | 2 January 2012
NovaBiotics reveals plans for cystic fibrosis drug after EU grants orphan status | 19 December 2011
Pharmacells stores stem cells for teenager paralysed in car crash | 20 October 2011
NovaBiotics Ltd - Presentation at BIO International 2011, Washington DC | 24 June 2011
Launch of Oristem® | 04 June 2011
GBP in Nexxus newsletter, Spring 2011 | 22 March 2011
Patents granted in key territories as Novexatin® moves closer to further clinical development and commercialisation | 21 February 2011
Unblinded Phase IIa Clinical Trial Data Delivers Excellent Results for Novexatin®, Nova... | 5 July 2010
Successful Completion of Phase IIa clinical trial for Novexatin®, IND filing planned for Phase IIb... | 1 May 2010
NovaBiotics Announces New Data on Cysteamine (Nylexa™)
18th June 2016
NovaBiotics Wins Investment of the Year Award
5th February 2016
Launch of the BEAM Alliance
9th June 2015
NovaBiotics Quoted in "What Investment" on 11 February
11th February 2015
Showcases increasing investor interest in the global stem cell sector
22nd September 2014
NovaBiotics' Dr Deborah O'Neil Wins Entrepreneur of the Year
27th June 2014